(Q38193198)

30 August 2017

1 reference

title

Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection (English)

1 reference

30 August 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24593285%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Antonio Riccardo Buonomo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24593285%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Giuseppe Castaldo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24593285%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

author name string

Federico Borgia

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24593285%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Guglielmo Borgia

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24593285%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

language of work or name

English

0 references

publication date

4 March 2014

1 reference

Expert Opinion on Investigational Drugs

30 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24593285%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24593285%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24593285%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

561-571

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24593285%20AND%20SRC:MED&resulttype=core&format=json

Association of tattooing and hepatitis C virus infection: a multicenter case-control study.

8 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Age and gender distribution of hepatitis C virus genotypes in the metropolitan area of Naples

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Natural history of acute and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Sustained virological response: a milestone in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Surrogate endpoints and non-inferiority trials in chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Efficacy of Pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bio

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Current prospects for interferon-free treatment of hepatitis C in 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Profile of alisporivir and its potential in the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Perspectives and challenges of interferon-free therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Antiviral strategies in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Emerging treatments for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Specifically targeted antiviral therapy for hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

NS5A inhibitors in the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Unravelling hepatitis C virus replication from genome to function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Replication of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

Treating chronic hepatitis B: today and tomorrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892581

10.1517/13543784.2014.892581

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24593285%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

1 reference